Credit rating of the Company and its material subsidiary.
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Infomerics Valuation and Rating Limited has reaffirmed credit ratings for Haleos Labs Ltd (parent) and its material subsidiary Mahi Drugs Private Limited on May 21, 2026. For Haleos Labs, the long-term rating is IVR BBB/Positive and short-term rating is IVR A3+, with total bank facilities increasing from Rs. 81.86 crore to Rs. 116.01 crore. For Mahi Drugs, the long-term rating is IVR BB+/Stable on facilities increasing from Rs. 10.83 crore to Rs. 20.75 crore. Both ratings were reviewed considering FY25 and 9MFY26 operational and financial performance. The ratings remain unchanged from the previous assessment with a positive/stable outlook.
The reaffirmation of investment-grade BBB rating with a Positive outlook for the parent company is a positive signal, indicating stable creditworthiness. The increase in bank facilities for both entities suggests growing business operations. The subsidiary's BB+ rating reflects higher credit risk but remains Stable, not indicating immediate concerns.